Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Axes Axid: Reliant Assumes U.S. Sales And Marketing Rights

Executive Summary

Reliant Pharmaceuticals' second adopted brand is the Lilly H2 antagonist Axid (nizatidine), a product with current annual sales of about $200 mil.

You may also be interested in...



Lilly Wins Axid Patent Ruling; Ivax Directed To Pay Attorneys Fees

Ivax must pay Lilly's attorney fees after a court ruling found that its challenge of the Axid (nizatidine) chemical compound patent was not based on "reasonable and good faith" assumptions

Lilly Wins Axid Patent Ruling; Ivax Directed To Pay Attorneys Fees

Ivax must pay Lilly's attorney fees after a court ruling found that its challenge of the Axid (nizatidine) chemical compound patent was not based on "reasonable and good faith" assumptions

Carter-Wallace Felbatol Successor Is Part Of R&D Rebuilding Under Wild

A successor to the anti-epileptic Felbatol is among the development projects for Carter-Wallace's healthcare unit following its acquisition by an investment firm run by former Warner-Lambert exec Anthony Wild.

UsernamePublicRestriction

Register

LL1134420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel